Drugs / Poly-gamma Glutamic Acid
Poly-gamma Glutamic Acid
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01826045 | Jun 2013 → Dec 2015 | cervical intraepithelial neoplasia | BioLeaders Corporation | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Poly-gamma Glutamic Acid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01826045 ↗ |
| Known as | PGA | “The treatment group will be administered with PGA (Poly-gamma Glutamic Acid) for 4 weeks followed by 8 weeks observation.” NCT01826045 ↗ |
| Known as | γ-PGA | “Participants were randomly assigned to one of two groups and orally treated with placebo or 1,500 mg of γ-PGA for 4 weeks.” PMID 31220105 ↗ Jun 2019 |
| Route | Oral | “Participants were randomly assigned to one of two groups and orally treated with placebo or 1,500 mg of γ-PGA for 4 weeks.” PMID 31220105 ↗ Jun 2019 |